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Abstract
Background: Nanomaterials are being manufactured on a commercial scale for use in medical,
diagnostic, energy, component and communications industries. However, concerns over the safety
of engineered nanomaterials have surfaced. Humans can be exposed to nanomaterials in different
ways such as inhalation or exposure through the integumentary system.
Results: The interactions of engineered nanomaterials with primary human cells was investigated,
using a systems biology approach combining gene expression microarray profiling with dynamic
experimental parameters. In this experiment, primary human epidermal keratinocytes cells were
exposed to several low-micron to nano-scale materials, and gene expression was profiled over
both time and dose to compile a comprehensive picture of nanomaterial-cellular interactions. Very
few gene-expression studies so far have dealt with both time and dose response simultaneously.
Here, we propose different approaches to this kind of analysis. First, we used heat maps and multi-
dimensional scaling (MDS) plots to visualize the dose response of nanomaterials over time. Then, in
order to find out the most common patterns in gene-expression profiles, we used self-organizing
maps (SOM) combined with two different criteria to determine the number of clusters. The
consistency of SOM results is discussed in context of the information derived from the MDS plots.
Finally, in order to identify the genes that have significantly different responses among different
levels of dose of each treatment while accounting for the effect of time at the same time, we used a
two-way ANOVA model, in connection with Tukey’s additivity test and the Box-Cox
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nanomaterials.
Conclusion: The analysis presented here lead to interesting and complementary conclusions
about the response across time of human epidermal keratinocytes after exposure to nanomaterials.
For example, we observed that gene expression for most treatments become closer to the
expression of the baseline cultures as time proceeds. The genes found to be differentially-
expressed are involved in a number of cellular processes, including regulation of transcription and
translation, protein localization, transport, cell c y c l ep r o g r e s s i o n ,c e l lm i g r a t i o n ,c y t o s k e l e t a l
reorganization, signal transduction, and development.
Background
Nanomaterials are being manufactured on a commercial
scale for use in medical, diagnostic, energy, component
and communications industries [1,2]. Engineered nano-
materials range considerably in their physicochemical
properties making them more desirable than their micro-
and macro-counterparts due to, for example, their
increased surface area, tensile strength, tunability, etc.
[3]. From limited early reports, concerns over the safety
of engineered nanomaterials have surfaced [4,5].
Humans can be exposed to nanomaterials in different
ways such as inhalation or exposure through the
integumentary system. However, the skin is a unique
organ in the body not only because it gives the body
such a large surface area for exposure but also because of
the avascular property of epidermis, in which particles
can reside without being removed by phagocytosis [6].
Gene expression microarrays have become a tool to
investigate the interactions of biological systems by
observing the simultaneous activities of tens of thou-
sands of genes. Over recent years, this tool has been
applied to toxicology forming a new discipline, toxico-
genomics [7,8]. Microarrays have most recently been a
tool used by pharmaceutical drug discovery and devel-
opment to screen for efficacy and adverse effects thereby
prioritizing drug candidates and redeveloping ones
which show off-target toxicities [9-11].
The approach described here combines a global screen-
ing technology, gene expression microarray profiling,
with systems biology, to investigate the interactions of
engineered nanomaterials with primary human cells. The
biological and cellular system is perturbed and reitera-
tively sampled over both time and dose to compile a
more comprehensive picture of nanomaterial-cellular
interactions. From over 100 papers which were reviewed
by the authors in [12], only 3 papers have dealt with the
effect of concentration plus time while the remaining
papers dealt only with the parameter of time. Initial
studies that were published previously focused on
reporting significantly-expressed genes and using
clustering methods to identify similarities and differ-
ences between expression profiles [13-15]. In addition,
the study cited in [12] was the only previously combined
study investigating time-course and dosage-effect simul-
taneously, while the initial 3 cited studies investigated
time-effect and dosage effect separately.
In the present study, we propose different approaches to
this kind of analysis. We considered the gene expression
of primary human epidermal keratinocytes, under
exposure to the following low-micron to nano-scale
materials: carbonyl iron (FC), carbon black (CB) silica
(SiO2) and single-walled carbon nanotubes (SWNT), at
noncytotoxic and cytotoxic doses for each. The nano-
materials used, except for the carbonyl iron (FC) and
SWNT, are not intended for medical use. These materials
are currently being used in construction materials,
consumer goods, and communications and IT applica-
tions. The FC nanoparticles were used as a negative
control compound and have been approved for use by
the FDA as a pharmaceutical carrier formulation. The
single-walled carbon nanotubes are being developed for
medical applications (e.g. drug carriers or medical
imaging compounds) only after being functionalized
with other components. We remark here that the goal of
the experimental design was not to study particle size or
penetration effects. It was to study whether there was an
overall interaction with the nanomaterials. In particular,
the cytotoxic dose (i.e. high dose) used with the carbonyl
iron was due to its toxic effect of an overload of iron on
the cells.
In the approach discussed here, we first used heat maps
and multi-dimensional scaling (MDS) plots to visualize
the dose response of nanomaterials over time. Then, in
order to find out the most common patterns in gene-
expression profiles, we used self-organizing maps (SOM)
combined with two different criteria to determine the
number of clusters. The consistency of the SOM results is
discussed in context of the results from the MDS plots.
Finally, in order to identify the genes that have
significantly different responses among the different
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effect of time, we have used a two-way ANOVA model, in
connection with Tukey’s additivity test and the Box-Cox
transformation. These analysis results are discussed in
the context of the biological and cellular interactions of
the engineered nanomaterials.
Methods
Biological experimental design
Primary human epidermal keratinocytes (HEK, Cascade
Biologics) were cultured with serum-free defined media
at 5% CO2 and 37°C. The HEK were exposed to the
following low-micron to nano-scale materials: carbonyl
iron (FC), carbon black (CB) silica (SiO2)a n ds i n g l e -
walled carbon nanotubes (SWNT). FC was supplied by
ISP Technologies with a mean particle size of 5.8 μm, CB
was supplied by Degussa with a mean particle size of
17 nm, and SiO2 was supplied by US Silica with a mean
particle size of 1.6 μm. SWNT was prepared by South-
West Nanotechnologies with a mean diameter of 0.8 nm.
The purity of SWNT was checked, and it was found that
all heavy metal contamination was very low, less than
1%. The nanotubes were acid-purified from the raw
manufactured intermediate. The average length of the
SWNT nanotubes was 960 nm; this is the only
nanomaterial among the ones considered here that is
not spherical. From previous viability assays [13,15], two
different doses were selected for the exposure of each
nanomaterial – a noncytotoxic dose and a cytotoxic
dose. The cytotoxic dose was extrapolated from the
viability curve of each substance where 50% of the cells
were still viable. The noncytotoxic and cytotoxic doses
for each nanomaterial were found to be, respectively,
0.03 and 1 (FC), 0.01 and 0.5 (CB), 0.1 and 1 (SiO2),
and 0.001 and 1 (SWNT), all concentrations being
expressed in mg/ml. The cells were exposed to FC, CB,
SiO2, and SWNT and harvested at 2, 4, 6, 8, 12, 18, and
24 hours after exposure. Cells cultured under the same
conditions and not exposed to any of the nanomaterials
were harvested at the same time points for a time-
matched control baseline.
The cells were trysinized and cell counts taken. The cells
were then collected by centrifugation, snap frozen in
l i q u i dn i t r o g e n ,a n ds t o r e da t80°C. The frozen pellets
were shipped to GenUs Biosystems for isolation of the
total RNA and processing of the gene expression
microarrays. Total RNA was isolated from the cell pellets,
reverse-transcribed to biotinylated cRNAs and hybri-
dized onto 10 K human gene expression microarrays (GE
Healthcare). The corresponding cRNA for each biological
sample was hybridized to triplicate microarrays. The
arrays were rinsed, dried, scanned and image analyzed
and the flat files returned to the Houston Advanced
Research Center.
Data analysis and preprocessing
The microarray flat files contained the quantitative
expression values for all probes (positive controls,
negative controls, fiducial, and discovery) and all
discovery probe values were assessed with a quality
flag. Only those probes that have ”DISCOVERY” and ”G”
(Good-quality) tags across all time points and dose
levels of all treatments were considered for further
analysis to guarantee maximal reproducibility of the
results. By using this criterion, the number of genes was
reduced from 10,458 to 2,370. Then the average of the
three replicate measurements was considered as the
actual expression level of each gene at that time in its
corresponding treatment.
Heatmaps
The heatmaps are visualizations of hierarchical clustering
[16] using ”average” linkage and Pearson Correlation as
the distance metric between expression levels of each
gene after taking the log ratio of the data. It is worthy to
mention that Pearson correlation is in fact the normal-
ized correlation between values of two random variables
that have had their mean subtracted from them. The
dendrogram added to the left side of each heat map is
obtained by Pearson correlation. The heatmaps were
drawn by first subtracting the mean of each row from
each data cell and then normalizing each row to obtain a
variance of 1. Note that normalization was performed
after taking the log ratio of the expression of each gene
between the given treatment and the control baseline.
Heatmaps obtained in this way reveal the underlying
shape of expression pattern of genes better and are less
affected by some large values which may be the result of
noise. For more information on applying hierarchical
clustering to gene expression patterns, see [16] and [17]
and the references mentioned there.
Multi-dimensional Scaling (MDS)
Multidimensional Scaling (MDS) is a method to project
high dimensional data onto a lower dimension while
maintaining the approximate distances between data
points [21]. The accuracy of the representation is
measured by the ”stress.” A stress of 10% is usually
considered good.
First, the data are collected by taking the log of the
expression values of genes in each treatment and the
baseline. Then at each time point, a matrix of distances
between the gene-expression profiles corresponding to
each treatment and the baseline is created, where the
BMC Bioinformatics 2009, 10(Suppl 11):S10 http://www.biomedcentral.com/1471-2105/10/S11/S10
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between the profiles. Finally, MDS is performed based
on this matrix, in order to obtain a low-dimensional
representation of the gene-expression profiles and the
distance among them.
Self-Organizing Maps (SOM)
SOM [15] is a powerful method for clustering. After log-
normalizing the data as explained above, this method
was employed in two ways.
First, the underlying hidden number of clusters of the
data was estimated using two different criteria the
silhouette criterion [18] and the CLEST criterion [19].
In [19], it has been shown that the CLEST criterion is the
stronger tool to find number of clusters. However, from
the comparison of the CLEST and the silhouette criteria
in [19], it is inferred that whenever the true number of
clusters has been equal to 2, the silhouette criterion is
the same as the CLEST or has done a better job than the
CLEST criterion, while for greater number of clusters, the
CLEST performs better. Therefore, the criterion that we
have used to determine the number of clusters is a
combination of the two criteria. First, the silhouette
criterion is implemented to determine the number of
clusters. If the number of clusters for any treatment is
equal to 2, and if the silhouette width for this number of
clusters is fairly close to 1 (e.g. greater than 0.6) then we
assigned 2 as the optimal number of clusters. Otherwise,
the CLEST criterion is implemented to determine the
number of clusters.
In the second way of implementing SOM, larger
numbers of clusters than the previous approach were
tried, as a means of obtaining clusters that show tighter
expression patterns than in the first approach.
ANOVA model
A two-way ANOVA model was used to identify genes for
which there are significant differences in the response
to the various dose levels, and have them ranked by
the p-values of dose main effect. The general procedure
w a sa sf o l l o w s :
0 – For each gene, compile the data in a two-
dimensional array consisting of the expression values
from the three levels of dose (untreated, low and
high) and the eight time points. Use Tukey’s
additivity test for two-way ANOVA (one observation
per cell) to see if there is interaction between time
and dose for the given gene. If there is no interaction
go to step 2.
1 – If there is significant interaction between these
two factors, try to remove the interaction by using the
Box-Cox transformation [20]. The removal of inter-
action can be tested by Tukey’s additivity test for
transformed values corresponding to each parameter
of the Box-Cox transformation. We have chosen this
parameter to vary between -2 to 2 with 0.1 spacing. If
the interaction is removed, use these as the new data
for the given gene. If the interaction could not be
removed, set the p-value of dose main effect to NA
and go to step 0 to start the process for the next gene.
2 – U s et w o - w a yA N O V At of i n dw h e t h e rt h e r ea r e
significant differences among the levels of the dose
and time factor. If there is not any significant
difference on any factor, go to step 4.
3 – Use Tukey’s HSD post-hoc test to determine
between which levels of either factor there are
significant differences and record them. Since Tukey’s
HSD test is conservative, in rare cases the test cannot
find any significant difference between levels.
4 – Save the p-value for the difference in dose main
effect for this gene and go to step 0 to start the
process for the next gene.
At the end of this process, sort all genes with respect to
p-values on dose main effect. The lower the p-value is
for a gene, the stronger the evidence is that there are
significant differences in response among the various
levels of dose for that gene.
Results
A. Heatmap plots
For the heatmaps, we consider the log ratio between the
gene expression in one of the treatment time-courses
and the corresponding gene expression in the baseline
time-course, for each gene and each time point, and plot
the log ratio for each gene (rows) versus time point
(columns). There are 8 heatmaps, corresponding to each
of the 8 treatments (including low and high dose),
which are displayed in Figures 1 and 2. In these plots,
the closer the color of a cell is to white (positive log
ratio, up-regulation) and red (negative log ratio, down-
regulation), the more difference there is between the
expression value of that gene between the given
treatment and the baseline at the particular time point;
by contrast, orange indicates an absence of differential
expression with respect to the baseline. Considering, for
instance, the SiO2 LD (low dose) heatmap, we can see
that differential expression tends to occur early in the
time course (between 0 and 4 hr) and tends to disappear
with time. It can also be observed in this heatmap that
the genes fall in basically two clusters with respect to
their time-course expression: a majority of genes that are
up-regulated early, and a minority that is down-
regulated early and slightly up-regulated later in the
time course.
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For the MDS plots, we consider the log of the absolute
gene expression for each of the treatments and the
baseline (no ratio is taken). There are 7 plots, one for
each time point, which are displayed in Figures 3 and 4.
In these plots, the closer two points are to each other,
the more similar their gene expression profiles are,
according to the Pearson correlation (see Methods
section). Considering, for instance, the plot at time
18 hrs, it can be easily seen that most of the
Figure 1
Heat map and Hierarchical Clustering for the high-dose treatments.
BMC Bioinformatics 2009, 10(Suppl 11):S10 http://www.biomedcentral.com/1471-2105/10/S11/S10
Page 5 of 13
(page number not for citation purposes)treatments show similar gene expression to the base-
line at this time (i.e., a weak transcriptional response),
while the CB HD (high dose) and FC HD treatments
present a stronger response. This is clear by the fact
that all the treatments are concentrated in one point
except CB HD and FC HD. In fact, one observes that
a l lt r e a t m e n t st e n dt ob e c o m ec l o s e rt ot h eb a s e l i n ea s
time proceeds, except for CB HD and FC HD. This
shows that these two treatments, generally, have the
most effect on changing gene expression. The same
Figure 2
Heat map and Hierarchical Clustering for the low-dose treatments.
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and 2.
C. Self-Organizing Maps (SOM)
Here, we again consider the log ratio between the gene
expression in one of the treatment time-courses and the
corresponding gene expression in the baseline time-
course, for each gene and each time point. Table 1 shows
the optimal number of clusters for each treatment that
were obtained by using a combination of the silhouette
and CLEST criteria, as described in the Methods section.
It is interesting to compare these numbers with what is
deduced from visualizing the heatmaps in Figures 1
and 2. For example, Table 1 says that the number of
clusters in SiO2 LD and CB HD is 2 and 4, respectively.
This fact is consistent with what one may infer from
Figures 1 and 2.
Figure 5 shows the average expression values of genes in
each cluster by performing SOM on the CB HD
Figure 3
Sequence of MDS plot from time 2 hr to 8 hr.
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t h el i s to fg e n e si ne a c hc l u s t e r ,c a nb ef o u n di nt h e
supplementary information). In agreement with the fact
that the optimal number of clusters in this treatment was
determined to be four, we employed 2 × 2 SOM to find
four clusters. This can be contrasted with Figure 6, which
shows the result for the same treatment but now using 5 ×
6 SOM to find 30 clusters. Obviously, as there are fewer
genes in each cluster, we obtain tighter gene expression
patterns (smaller standard deviations) in each cluster.
D. ANOVA model
The two-way ANOVA model that we consider has as
factors time and dose, where the former has 3 levels
(baseline, low dose and high dose) and the latter has
7 levels, corresponding to the seven time points in the
experimental design. Since we are interested in the dose
main effect on a given gene, we attempt to remove
interaction of dose with time. After determining those
genes affected significantly by the dose main effect, it is
worthy to investigate between which specific levels there
Figure 4
Sequence of MDS plot from time 12 hr to 24 hr.
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HSD post-hoc test (see the Methods section for a
detailed description of the procedure that was
employed).
Table 2 show the top 40 gene IDs that respond to the CB
HD treatment, out of the original list of 2370 genes (the
tables for the other treatments can be found in the
supplementary information). The genes were ranked in
ascending order of the p-value resulting from the ANOVA
analysis, which means that the genes at the top are
expected to show stronger responses to the treatment. In
addition, the last three columns of Table 2 show where
the expression differences lie, according to Tukey’sH S D
test; ”1” indicates a significant difference.
Discussion
We comment here on the results obtained for the various
treatments. The analysis resulted in several gene families
or genes associated with the same cellular processes
which responded significantly to the treatments. Very
little toxicity overall was seen with any nanomaterial at
the noncytotoxic dose except for silica, the positive
control substance. Pathways for inflammation and
irritation were identified; e.g., these pathways were
observed for the silica at a noncytotoxic dose. At the
cytotoxic doses, the most toxicity was seen with carbonyl
iron – the explanation for this being the iron overload
experienced by the cells. On the other hand, the majority
of the genes found show significant differences at both
the low and high dose levels. We observed that gene
expression level becomes closer to basal level in later
time points. This trend is seen with all gene expression
profiling where the initial hours show the most activity
[49,50].
Next we provide next detailed comments on the genes
displayed in Table 2, which are associated with
significant response to the CB treatment. Many of these
genes are notable. Three different chromodomain-heli-
case-DNA binding protein genes are seen: CHD2, CHD3
and CHD4. These genes code for proteins which form a
histone deacetylase complex involved in chromatin
remodeling, an important transcriptional process [22].
Two different genes coding for proteins in the protein
tyrosine phosphatase or protein tyrosine phosphatase-
like families, PTP1B and PTPLB, are found to be highly
significant. In addition, four genes associated with
apoptosis are found. IL1A and TRADD are both involved
in the NF-KappaB signaling pathways [23,24]. NR4A1 is
an early response gene which codes for a nuclear orphan
receptor and has an active role in cellular stress [25].
TAF9 is a TATA box-binding protein associated factor
binds histones and is important in transcriptional
regulation and cell viability [23-26]. Additionally,
another protease, PSME4, which is related to the
ubiquitin pathway, was found [27]. STX1A is a gene
that may be involved Parkinson’s disease as it translates
to proteases located in brain tissue [28]. The gene PAIP1
is involved in the regulation of translation. PAIP1 is very
similar to EIF4A (an eukaryotic initiation factor) which
has a role in binding mRNA molecules to the ribosome.
PAIP1 is active in mRNA turnover and their dead-
enylation and decay [29]. One gene, FRAG1, appears
twice as two different FRAG1 probes were found to be
significant within the top 40 genes.
Genes that show differential expression at both dose
levels include MAPK8IP3, TRIO, ATP6V1F, and Hs.
656094 (gene index 2145). TRIO regulates the reorgani-
zation of the cytoskeleton and is essential for cell
migration and cell growth [30]. ATP6V1F is active in
transport mechanisms; it mediates the acidification of
intracellular compartments essential to ion transport
across cellular membranes [31,32]. MAPK8IP3 is
Table 1: Treatments and the their determined optimal number
of clusters
Treatment Number of Clusters
CB HD 4
CB LD 5
FC HD 2
FC LD 3
Sio2 HD 10
Sio2 LD 2
SWNT HD 3
SWNT LD 5
Figure 5
SOM clusters for a 2 × 2 unit plane for CB HD.
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protein in the JNK signaling pathway [33]. It is activated
by cytokines and environmental stresses. One gene (Hs.
656094, gene index 2145) is unannotated, being a
transcribed locus that translates to a protein with no
known functions.
Several genes show differential expression only with the
high dose. These genes include IL1A, LAMB2, IMPA1,
ARID5B, CHD4 and ARHGAP22. The genes ARHGAP22,
ARID5B and CHD4 are involved in the regulation of
transcription. ARHGAP22 codes for a rac GPTase active
in signal transduction and seems to play an indirect role
Figure 6
SOM clusters for a 5 × 6 unit plane for CB HD.
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ARID5B regulates transcription by binding to DNA and
has important roles in development and differentiation
[35]. CHD4 represses transcription by modulating the
amount of protein at the centrosome during mitosis [36].
IL1A is involved in apoptosis as well as many roles in
immune and inflammatory responses and hematopoiesis
[ 3 7 ] .T h el a s tt w og e n e s ,L A M B 2a n dI M P A 1a r eb o t h
involved in development. IMPA1 has an essential role in
phosphatidylinositol pathways and LAMB2 codes for a
laminin isoform which is involved in embryonic devel-
opment and the organization of cells into tissues [38].
Table 3 breaks down where differences are found among
the 40 genes on the top of list of each treatment. It can be
seen from this table that CB is a treatment under which
there appear to be stark differences in gene expression
between all dose levels. On the other hand, most of the
response due to exposure to FC occurs under a high dose
level, the differences between low dose and no treatment
having a much smaller representation. For SiO2 and
SWNT, most of the difference is between high or low
dose (it does not matter) and no treatment. These
observations are consistent with what was inferred from
the heatmaps and MDS plots in Figures 1, 2, 3, and 4.
Table 2: Genes showing significant difference among various level of dose in treatment CB
Rank Acc No. Entrez Gene ID Gene Name HD-LD HD-Control LD-Control
1 AB023163 23390 ZDHHC17 1 1 1
2 NM_033495 90293 KLHL13 1 1 1
3 AL390214 7204 TRIO 1 1 1
4 BF057080 – ENPP1 1 1 1
5 NM_002292 3913 LAMB2 1 1 0
6 NM_004231 9296 ATP6V1F 1 1 1
7 NM_004524 3993 LLGL2 1 1 1
8 U91543 1107 CHD3 1 1 1
9 AF052159 201562 PTPLB 1 1 0
10 AL049471 – ARID5B 1 1 0
11 NM_001461 2330 FMO5 1 1 1
12 NM_002135 3164 NR4A1 1 1 0
13 NM_002827 5770 PTP1B 1 1 1
14 NM_004517 3611 ILK 0 1 1
15 NM_014489 27315 FRAG1 1 1 1
16 AL049218 – RNASEH2B 1 1 1
17 BC013306 6923 TCEB2 1 1 1
18 D38521 23198 PSME4 1 1 1
19 NM_001273 1108 CHD4 1 1 0
20 NM_003789 8717 TRADD 1 1 1
21 NM_005374 4355 MPP2 0 1 1
22 NM_007112 7059 THBS3 1 1 1
23 AF090094 – OAZ1 0 1 1
24 NM_000575 3552 IL1A 1 1 1
25 NM_003187 6880 TAF9 1 1 1
26 NM_005309 2875 GPT 1 1 1
27 NM_006451 10605 PAIP1 1 1 0
28 NM_022365 64215 DNAJC1 1 1 1
29 AI435998 – C17orf51 1 1 1
30 AW021631 – ——————— 11 1
31 NM_004603 6804 STX1A 1 1 0
32 NM_005182 766 CA7 1 1 1
33 AA601902 – MAPK8IP3 1 1 1
34 AL137484 221191 KLKBL4 1 1 1
35 NM_001271 1106 CHD2 1 1 1
36 NM_005536 3612 IMPA1 1 1 0
37 X58529 3507 IGHM 0 1 1
38 NM_014489 27315 FRAG1 1 1 1
39 NM_016574 1813 DRD2 1 1 1
40 NM_023111 2260 FGFR1 1 1 1
Table 3: Number of genes that have significant differences among
the top 40 genes
HD-LD HD-Cont. LD-Cont.
CB 36 40 32
FC 40 40 7
SiO2 25 40 40
SWNT 27 40 39
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The analysis presented here lead to interesting and
complementary conclusions about the response across
time of human epidermal keratinocytes after exposure
to nanomaterials. For example, we observed (especially
through the time sequence of MDS plots) that gene
expression for each treatment become closer to the
expression of the baseline cultures as time proceeds,
except for CB HD and FC HD, which generally have
the most changing expression levels. The results from
the MDS analysis mostly confirmed the results from the
heatmaps and SOM clustering. The genes found to be
differentially-expressed by the ANOVA analysis are
involved in a number of cellular processes, including
regulation of transcription and translation, protein
localization, transport, cell cycle progression, cell migra-
tion, cytoskeletal reorganization, signal transduction,
and development. The majority of these genes show
significant differences at both the low and high dose
levels.
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